Abstract
Aim: Pooled efficacy studies suggest that glycaemic responses to dipeptidyl-peptidase 4 inhibitors in type 2 diabetes are greatest in Asians, who may ......
小提示:本篇文献需要登录阅读全文,点击跳转登录